|
Publisher: Orient Health Electronic Commercial(Beijing)co.,Ltd
Published: June 2007
Format: Adobe PDF
Price: US$ 1,600
Contact: Mr. Bian chenghua Ms. Wu huifang
Tel.: 86-10-68012929-2116/2101 Fax: 86-10-68052525
E-mail: bianch@healthoo.com wuhf@healthoo.com
Tables of contents
Summary
First part：Categories and their definitions of drugs for peptic ulcer
1 Categories of stomach diseases and the epidemic trend
2 Overview of drugs for peptic ulcer
Second part：Sales statistic in sample hospitals
1 Market scale and growth trend of drugs for stomach diseases
2 Market scale and growth trend of drugs for peptic ulcer in the past 4 years (2002～2006)
2.1 Market scale and growth trend
2.2 Market shares of different categories
2.3 Market shares of different products belonging to H2 Receptor Antagonists
2.4 Analysis on key products (H2 Receptor Antagonists) and enterprsies
Famotidine
Cimetidine
Bismuth Potassium Citrate/Ranitidine
Ranitidine
Nizatidine
Third part：Sales statistic of retail market for stomach diseases
1 Market shares of different categories for stomach diseases
2 Market shares of different brands in key cities
Forth part：Information of R&D
1 New drugs and trial drugs in world
2 R&D in China
2.1 List of Domestic marketd products and import procucts
2.2 Status of application and approval
Appendix
Appendix 1: Reference retail prices of popular stomach drugs
Appendix 2: The products listed in Drug Catalogue of National Basic Medical Insurance
Appendix 3: Infromation of application and approval for stomach drugs
Tables and figures
Table 1 Classification of drugs for peptic ulcer by action mechanism
Table 2 Classification of drugs for peptic ulcer by action progress
Table 3 Market shares of different categories for petic ulcer drugs
Table 4 Sale and growth of different categories of stomach drugs (2002-2006)
Table 5 Sale and growth of drugs for peptic ulcer in sample hospitals (2002-2006)
Table 6 Sale situation of different categories of peptic ulcer drugs (2002-2006)
Table 7 Sales rank of peptic ulcer drugs (2002-2006)
Table 8 Sale and growth of peptic ulcer drugs belonging to H2 receptor antagonists (2002-2006)
Table 9 Maket shares of key peptic ulcer drugs in 2006
Table 10 Maket shares of enterprises producing Famotidine in 2006
Table 11 Maket shares of enterprises producing Cimetidine in 2006
Table 12 Maket shares of enterprises producing Bismuth Potassium Citrate/Ranitidin in 2006
Table 13 Maket shares of enterprises producing Ranitidine in 2006
Table 14 List of enterprises Which recived the approval for Nizatidine
Table 15 Sales rank of retail drugs for gastrointestinal diseases in Shanghai in 2006
Table 16 Sales rank of enterprises in retail market of gastrointestinal drugs in Shanghai in 2006
Table 17 Sales rank of retail drugs for gastrointestinal diseases in Shenyang in 2006
Table 18 Sales rank of enterprises in retail market of gastrointestinal drugs in Shenyang in 2006
Table 19 Sales rank of retail drugs for gastrointestinal diseases in Qingdao in 2006
Table 20 Sales rank of enterprises in retail market of gastrointestinal drugs in Qingdao in 2006
Table 21 The amount of enterprises producing stomach drugs
Table 22 Products under the examination and approval by SFDA
Table 23 Reail prices of polualr stomach drugs
Table 24 List of the products in Drug Catalogue of National Basic Medical Insurance
Figure 1 Market scale and growth trend of drugs for stomach diseases 2002-2006
Figure 2 Sales values of different categories of stomach drugs 2002-2006
Figure 3 Market shares of different categories of stomach drugs 2002-2006
Figure 4 Total sales values of drugs for peptic ulcer 2002-2006
Figure 5 Sales values of different categories of peptic ulcer drugs 2002-2006
Figure 6 Sales share of different categories of peptic ulcer drugs 2002-2006 (Ranking by sales value)
Figure 7 Sales shares of different categories of peptic ulcer drugs 2002-2006 (Ranking by sales amount)
Figure 8 Sales growth of H2 receptor antagonist 2002-2006
Figure 9 Sales values of different H2 receptor antagonists 2002-2006
Figure 10 Sales amounts of different H2 receptor antagonists 2002-2006
Figure 11 Sales shares of different H2 receptor antagonists 2002-2006 (Ranking by sales value)
Figure 12 Sales shares of different H2 receptor antagonists 2002-2006 (Ranking by sales amount)
Figure 13 Market shares of different categories of peptic ulcer drugs in 2006
Figure 14 Market share of H2 receptor antagnists in 2006
Figure 15 Maket shares of enterprises producing Famotidine in 2006
Figure 16 Maket shares of enterprises producing Cimetidine in 2006
Figure 17 Maket shares of enterprises producing Bismuth Potassium Citrate/Ranitidin in 2006
Figure 18 Maket shares of enterprises producing Ranitidine in 2006
Figure 19 Maket shares of enterprises producing Nizatidine in 2006
Figure 21 Shares of different categories of retail drugs for gastrointestinal diseases in Shanghai in 2006
Figure 22 Shares of different categories of retail drugs for gastrointestinal diseases in Shenyang in 2006
Figure 23 Shares of different categories of retail drugs for gastrointestinal diseases in Qingdao in 2006
| 